Log In
BCIQ
Print this Print this
 

20-(74)-(74)

  Manage Alerts
Collapse Summary General Information
Company Immunomedics Inc.
DescriptionBispecific hexavalent antibody generated via the dock and lock (DNL) method that consists of 4 antigen-binding regions of milatuzumab, a humanized anti-CD74 antibody, conjugated to veltuzumab, a humanized anti-CD20 antibody
Molecular Target CD74 molecule major histocompatibility complex class II invariant chain ; CD20
Mechanism of ActionBispecific antibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationMantle cell lymphoma (MCL)
Indication DetailsTreat mantle cell lymphoma (MCL)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today